A study using a TIGIT-Fc fusion protein, which exerted immunosuppressive effects by binding to CD155 on DCs, demonstrated that TIGIT-Fc delayed the onset of GVHD symptoms and increased survival in model mice with acute GVHD. Here, TIGIT is linked to acute graft versus host disease.